Phase II Study of Combination Chemotherapy with Etoposide and Ifosfamide in Patients with Heavily Pretreated Recurrent or Persistent Epithelial Ovarian Canceropen access
- Authors
- Kang, H[Kang, Heeseok]; Kim, TJ[Kim, Tae-Joong]; Choi, CH[Choi, Chel Hun]; Lee, JW[Lee, Jeong-Won]; Lee, JH[Lee, Je-Ho]; Bae, DS[Bae, Duk-Soo]; Kim, BG[Kim, Byoung-Gie]
- Issue Date
- Oct-2009
- Publisher
- KOREAN ACAD MEDICAL SCIENCES
- Keywords
- Ovarian Neoplasms; Salvage Therapy; Etoposide; Ifosfamide
- Citation
- JOURNAL OF KOREAN MEDICAL SCIENCE, v.24, no.5, pp.945 - 950
- Indexed
- SCIE
SCOPUS
KCI
- Journal Title
- JOURNAL OF KOREAN MEDICAL SCIENCE
- Volume
- 24
- Number
- 5
- Start Page
- 945
- End Page
- 950
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/76869
- DOI
- 10.3346/jkms.2009.24.5.945
- ISSN
- 1011-8934
- Abstract
- The aim of this trial was to investigate the efficacy and toxicity of combination chemotherapy with etoposide and ifosfamide (ETI) in the management of heavily pretreated recurrent or persistent epithelial ovarian cancer (EOC). Patients with recurrent or persistent EOC who had measurable disease and at least two prior chemotherapy participating in this phase I I trial were to receive etoposide at a dose of 100 mg/m(2)/day intravenously (IV) on days 1 to 3 in combination with ifosfamide 1 g/m(2)/day IV on days 1 to 5, every 21 days. Thirty-seven patients were treated; about 78% had previously received more than two separate regimens. The response rate (RR) was 18.9% and median duration of response was 7 months (range, 1-15). Treatment free interval prior to ETI (TFI) has significant correlation with RR rate (P=0.034). Patients (n=6) with TFI >= 6 months had 50% of RR, while patients (n=31) with TFI <6 months had 12.9%. Median survival was 9 months at a median follow-up of 9.2 months. Grade 3 or 4 toxicities included neutropenia in 20.1% of the 139 cycles of ETI, anemia in 7.2% and thrombocytopenia in 8.6%. The ETI produces relatively low toxicity and modest activity in heavily pretreated recurrent or persistent EOC. This is significant in patients with TFI >= 6 months.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.